Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2018159787) PRODUCTION METHOD FOR DISEASE MODEL NON-HUMAN ANIMAL, DISEASE MODEL NON-HUMAN ANIMAL, DRUG SCREENING METHOD USING DISEASE MODEL NON-HUMAN ANIMAL, AND DISEASE RISK DETERMINATION METHOD
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2018/159787 International Application No.: PCT/JP2018/007901
Publication Date: 07.09.2018 International Filing Date: 01.03.2018
IPC:
A01K 67/027 (2006.01) ,A61K 45/00 (2006.01) ,A61P 1/04 (2006.01) ,A61P 9/04 (2006.01) ,A61P 25/00 (2006.01) ,G01N 33/15 (2006.01) ,G01N 33/50 (2006.01)
A HUMAN NECESSITIES
01
AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
K
ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
67
Rearing or breeding animals, not otherwise provided for; New breeds of animals
027
New breeds of vertebrates
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
45
Medicinal preparations containing active ingredients not provided for in groups A61K31/-A61K41/132
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
1
Drugs for disorders of the alimentary tract or the digestive system
04
for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
9
Drugs for disorders of the cardiovascular system
04
Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
25
Drugs for disorders of the nervous system
G PHYSICS
01
MEASURING; TESTING
N
INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33
Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
15
Medicinal preparations
G PHYSICS
01
MEASURING; TESTING
N
INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33
Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48
Biological material, e.g. blood, urine; Haemocytometers
50
Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
Applicants:
国立大学法人北海道大学 NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY [JP/JP]; 北海道札幌市北区北8条西5丁目 Kita 8-jyo Nishi 5-chome, Kita-ku, Sapporo-shi, Hokkaido 0600808, JP
Inventors:
村上 正晃 MURAKAMI Masaaki; JP
上村 大輔 KAMIMURA Daisuke; JP
有馬 康伸 ARIMA Yasunobu; JP
Agent:
特許業務法人IPアシスト特許事務所 IP-ASSIST PATENT OFFICE; JP
Priority Data:
2017-03811501.03.2017JP
Title (EN) PRODUCTION METHOD FOR DISEASE MODEL NON-HUMAN ANIMAL, DISEASE MODEL NON-HUMAN ANIMAL, DRUG SCREENING METHOD USING DISEASE MODEL NON-HUMAN ANIMAL, AND DISEASE RISK DETERMINATION METHOD
(FR) PROCÉDÉ DE PRODUCTION D'UN ANIMAL NON HUMAIN MODÈLE DE MALADIE, ANIMAL NON HUMAIN MODÈLE DE MALADIE, PROCÉDÉ DE CRIBLAGE DE MÉDICAMENT UTILISANT UN ANIMAL NON HUMAIN MODÈLE DE MALADIE, ET PROCÉDÉ DE DÉTERMINATION DE RISQUE DE MALADIE
(JA) 疾患モデル非ヒト動物の製造方法、疾患モデル非ヒト動物、該動物を用いた薬剤のスクリーニング方法及び疾患リスク判定方法
Abstract:
(EN) [Problem] The purpose of the present invention is to provide: a method for making an animal that has been stressed, and, in particular, chronically stressed, contract or present a specific disease or symptoms; and a tool that, by elucidating the process by which the stress leads to contracting or presenting the disease or symptoms, is useful for research and development related to the prevention or treatment of the disease or symptoms. [Solution] The present invention relates to: a production method for a disease model non-human animal that has inflamed intracerebral blood vessels; the disease model non-human animal; a drug screening method that uses the disease model non-human animal; a disease risk determination method that uses the presence of inflamed blood vessels as an indicator; and a pharmaceutical for preventing and/or treating progressive multiple sclerosis or the like. The present invention makes it possible to develop a pharmaceutical for the abovementioned disease or the like and to perform research to elucidate mechanisms of pathogenesis. The present invention also makes it possible to determine the risk of contracting or presenting progressive multiple sclerosis or the like and to prevent and/or treat progressive multiple sclerosis or the like.
(FR) Le but de la présente invention est de proposer : un procédé permettant d'amener un animal qui a été stressé, et en particulier stressé de façon chronique, à contracter ou à présenter une maladie ou des symptômes spécifiques; et un outil qui, par élucidation du processus par lequel le stress conduit à contracter ou à présenter la maladie ou les symptômes, est utile à la recherche et au développement liés à la prévention ou au traitement de la maladie ou des symptômes. La solution de la présente invention est un procédé de production d'un animal non humain modèle de maladie qui a des vaisseaux sanguins intracérébraux enflammés; l'animal non humain modèle de maladie; un procédé de criblage de médicament qui utilise l'animal non humain modèle de maladie; un procédé de détermination de risque de maladie qui utilise la présence de vaisseaux sanguins enflammés comme indicateur; et un produit pharmaceutique permettant de prévenir et/ou de traiter la sclérose en plaques progressive ou similaire. La présente invention permet de développer un produit pharmaceutique pour la maladie susmentionnée ou similaire et d'effectuer des recherches pour élucider des mécanismes de pathogenèse. La présente invention permet également de déterminer le risque de contracter ou de présenter une sclérose en plaques progressive ou similaire et de prévenir et/ou de traiter la sclérose en plaques progressive ou similaire.
(JA) 【課題】 本発明は、ストレス、特に慢性的なストレスを受けた動物に特定の疾患又は症状を罹患又は発症させる方法、そのストレスと疾患又は症状の罹患又は症状に至る過程の解明を通じて、当該疾患又は症状に対する予防又は治療等の研究開発に有用なツールを提供することを目的とする。 【解決手段】 本発明は、脳内血管に炎症を有する疾患モデル非ヒト動物の製造方法、当該モデル非ヒト動物、当該モデル非ヒト動物を用いた薬剤のスクリーニング方法、脳内血管の炎症の有無を指標とする疾患リスクの判定方法、並びに進行性多発性硬化症等を予防及び/又は治療するための医薬に関する。本発明によると、前記疾患等に対する医薬の開発や、発症機序解明のための研究が可能になる。また、進行性多発性硬化症等の罹患又は発症リスクの判定、並びに進行性多発性硬化症等の予防及び/又は治療が可能になる。
front page image
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: Japanese (JA)
Filing Language: Japanese (JA)